复发性-话题@MedSci

#复发性#

452篇内容 | 2497人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1909783, encodeId=3b9c1909e833e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效, objectType=article, longId=178017, objectId=010a1e801749, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=010a1e801749, replyNumber=0, likeNumber=77, createdTime=2020-07-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=010a1e801749, moduleTitle=Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=010a1e801749)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Nat Commun：复发性尿路感染中大肠杆菌ST131系群体动态研究, objectType=article, longId=178295, objectId=4b5d1e8295ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b5d1e8295ab, replyNumber=0, likeNumber=64, createdTime=2020-05-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b5d1e8295ab, moduleTitle=Nat Commun：复发性尿路感染中大肠杆菌ST131系群体动态研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b5d1e8295ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909777, encodeId=ea291909e772d, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=79, createdTime=2019-10-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909793, encodeId=53691909e93f4, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, objectType=article, longId=183027, objectId=fd5a18302e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd5a18302e46, replyNumber=0, likeNumber=113, createdTime=2020-09-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd5a18302e46, moduleTitle=NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd5a18302e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909795, encodeId=0c5b1909e952a, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, objectType=article, longId=183160, objectId=386c183160e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c183160e6, replyNumber=0, likeNumber=63, createdTime=2020-01-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c183160e6, moduleTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c183160e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909809, encodeId=57a3190980914, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, objectType=article, longId=190019, objectId=8870190019fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8870190019fe, replyNumber=0, likeNumber=56, createdTime=2020-12-06, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8870190019fe, moduleTitle=VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8870190019fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909782, encodeId=d9c61909e82eb, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=61, createdTime=2019-09-04, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909770, encodeId=ec861909e7031, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=NEJM：达比加群预防未确定来源栓塞性卒中患者的复发性卒中, objectType=article, longId=166194, objectId=4b0a1661946a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b0a1661946a, replyNumber=0, likeNumber=89, createdTime=2019-08-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b0a1661946a, moduleTitle=NEJM：达比加群预防未确定来源栓塞性卒中患者的复发性卒中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b0a1661946a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909781, encodeId=68881909e818b, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, objectType=article, longId=176195, objectId=60091e619534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60091e619534, replyNumber=0, likeNumber=66, createdTime=2019-11-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60091e619534, moduleTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60091e619534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909791, encodeId=92bf1909e91a6, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, objectType=article, longId=181868, objectId=ccf018186817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccf018186817, replyNumber=0, likeNumber=79, createdTime=2020-03-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccf018186817, moduleTitle=美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccf018186817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909802, encodeId=f7e8190980215, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：纳武单抗单药治疗有望治愈难治性/复发性EBV相关淋巴组织细胞增生症, objectType=article, longId=186026, objectId=bf6518602653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf6518602653, replyNumber=0, likeNumber=68, createdTime=2020-02-05, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf6518602653, moduleTitle=Blood：纳武单抗单药治疗有望治愈难治性/复发性EBV相关淋巴组织细胞增生症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf6518602653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909800, encodeId=ecaf190980086, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, objectType=article, longId=185337, objectId=697318533ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697318533ec4, replyNumber=0, likeNumber=91, createdTime=2020-03-11, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697318533ec4, moduleTitle=Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697318533ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909807, encodeId=b271190980e95, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Blood：进展性/复发性Burkitt淋巴瘤/白血病采用BFM型一线疗法治疗, objectType=article, longId=187522, objectId=84b818e5224c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b818e5224c, replyNumber=0, likeNumber=62, createdTime=2020-06-21, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b818e5224c, moduleTitle=Blood：进展性/复发性Burkitt淋巴瘤/白血病采用BFM型一线疗法治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b818e5224c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909768, encodeId=c6ea1909e6817, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, objectType=article, longId=164439, objectId=effa16443993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=effa16443993, replyNumber=0, likeNumber=75, createdTime=2019-06-20, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=effa16443993, moduleTitle=Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=effa16443993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909789, encodeId=10aa1909e895d, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Heart：复发性感染性心内膜炎的流行病学特征和预后, objectType=article, longId=180509, objectId=ed8318050950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8318050950, replyNumber=0, likeNumber=56, createdTime=2019-10-17, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8318050950, moduleTitle=Heart：复发性感染性心内膜炎的流行病学特征和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8318050950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909801, encodeId=888419098016d, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, objectType=article, longId=185399, objectId=b7f018539947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f018539947, replyNumber=0, likeNumber=62, createdTime=2020-02-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f018539947, moduleTitle=中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f018539947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909759, encodeId=19711909e59c0, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Sci Transl Med：复发性A型链球菌扁桃体炎是一种免疫敏感性疾病, objectType=article, longId=159796, objectId=4350159e96d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4350159e96d2, replyNumber=0, likeNumber=81, createdTime=2019-07-24, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4350159e96d2, moduleTitle=Sci Transl Med：复发性A型链球菌扁桃体炎是一种免疫敏感性疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4350159e96d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909775, encodeId=f8e81909e7535, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病, objectType=article, longId=167799, objectId=90c516e799ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c516e799ed, replyNumber=0, likeNumber=62, createdTime=2019-10-09, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c516e799ed, moduleTitle=Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c516e799ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909786, encodeId=80041909e86e6, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=王军教授：残留复发性甲状腺癌, objectType=article, longId=179921, objectId=b98b1e99217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b98b1e99217a, replyNumber=0, likeNumber=64, createdTime=2019-10-22, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b98b1e99217a, moduleTitle=王军教授：残留复发性甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b98b1e99217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1909796, encodeId=bf0e1909e96e4, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, objectTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, objectType=article, longId=183565, objectId=c2ab183565aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ab183565aa, replyNumber=0, likeNumber=87, createdTime=2020-02-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ab183565aa, moduleTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ab183565aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发性

2020-05-29

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效

2020-07-14

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Nat Commun：复发性尿路感染中大肠杆菌ST131系群体动态研究

2020-05-22

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2019-10-23

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

NEJM：二次手术不能延长铂敏感的复发性卵巢癌患者生存期

2020-09-27

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据

2020-01-18

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

VEGFR抑制剂Cediranib联合PARP抑制剂Lynparza治疗铂敏感复发性卵巢癌的III期试验失败

2020-12-06

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2019-09-04

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

NEJM：达比加群预防未确定来源栓塞性卒中患者的复发性卒中

2019-08-18

仁者大医 (审核中...)

前往app查看评论内容

#复发性#

Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期

2019-11-28

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

美国FDA批准Zejula（niraparib）用于复发性卵巢癌妇女的晚期治疗

2020-03-23

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：纳武单抗单药治疗有望治愈难治性/复发性EBV相关淋巴组织细胞增生症

2020-02-05

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Opdivo & Yervoy联合疗法在日本寻求治疗不可切除、晚期或复发性非小细胞肺癌

2020-03-11

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Blood：进展性/复发性Burkitt淋巴瘤/白血病采用BFM型一线疗法治疗

2020-06-21

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet haemat： Polatuzumab vedotin或Pinatuzumab vedotin联合利妥昔单抗用于复发性/难治性非霍奇金淋巴瘤的疗效

2019-06-20

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Heart：复发性感染性心内膜炎的流行病学特征和预后

2019-10-17

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

中国NMPA批准ZEJULA（Niraparib）用于复发性卵巢癌患者的维持治疗

2020-02-03

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Sci Transl Med：复发性A型链球菌扁桃体炎是一种免疫敏感性疾病

2019-07-24

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病

2019-10-09

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

王军教授：残留复发性甲状腺癌

2019-10-22

hb2008ye (审核中...)

前往app查看评论内容

#复发性#

2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据

2020-02-13

科室
- - 订阅+
  - 更多科室
工具
服务